BioPharma Clinical Trials
Suzhou Ribo Life Science And Insilico Medicine Forge Strategic Alliance To Accelerate AI Powered siRNA Drug Development
Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Me...
May 14, 2026 | News
Curocell And ProBio Achieve Korean Milestone With Approval Of Next Generation CAR T Therapy Anbal cel
Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation Given the accelerating global momentum in CAR-T and gene th...
May 13, 2026 | News
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...
May 13, 2026 | News
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...
May 13, 2026 | News
Innovent Secures Third Breakthrough Therapy Designation In China For IBI363 In Colorectal Cancer
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality med...
May 12, 2026 | News
Chance Pharma Advances First NDA Submission In China For Innovative Asthma Therapy CXG87
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...
May 11, 2026 | News
Rznomics Secures FDA RMAT Designation For RNA Editing Therapy RZ 001 In Liver Cancer
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...
May 11, 2026 | News
Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
May 11, 2026 | News
ABEC Expands Process Sciences Capabilities To Accelerate Bioprocess Development And Scale Up
ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...
May 08, 2026 | News
Taimei Technology And C&R Research Partner To Advance AI Driven Clinical Trial Operations In South Korea
Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Kore...
May 08, 2026 | News
Alebund Completes Global Phase III Enrollment For AP301 In Hyperphosphatemia Trial
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies...
May 07, 2026 | News
Cellenkos Advances CK0802 Into Phase 1b 2a Trial Following FDA Clearance For Steroid Refractory GVHD
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with s...
May 06, 2026 | News
EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma
EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...
May 05, 2026 | News
Australia Approves First RNAi Therapy For Familial Chylomicronemia Syndrome
– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...
May 05, 2026 | Report
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
